ArticleCureus2025
Predictors of Gallstones in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most prevalent chronic liver disease worldwide, particularly in South Asian countries like Pakistan. Gallstone disease (GSD), often associated with metabolic abnormalities, shares several risk factors with MAFLD, such as obesity, diabetes, and dyslipidemia. Despite international evidence supporting an association between MAFLD and GSD, there is a hdlscarcity of local data in this regard. Therefore, this study aimed to determine the independent predictors of GSD in MAFLD patients in Pakistan. Study methodology This cross-sectional study was conducted at the Hepatogastroenterology Department of Sindh Institute of Urology and Transplantation (SIUT) from January to December 2024. A total of 350 adults with the presence of fatty liver on ultrasound were enrolled. Patients with significant alcohol intake, those with known liver diseases, prior cholecystectomy, pregnancy, and use of lipid-altering medications were excluded from the study. Demographic, clinical, and laboratory parameters were recorded. Gallbladder stones were identified using abdominal ultrasound. Univariate analysis followed by multivariate logistic regression was performed to identify the independent predictors of GSD. Results Among 350 patients with MAFLD, 102 (29.1%) had gallstones. Patients with gallstones were significantly older (mean age 52.1 vs. 47.1 years, p<0.001), with a higher prevalence of female gender (63.7% vs. 35.4%, p<0.001) and diabetes mellitus (68.6% vs. 48.3%, p = 0.002). Laboratory markers including alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total cholesterol, triglycerides, and fasting blood sugar (FBS) were significantly elevated in the gallstone group, whereas high-density lipoprotein (HDL) was significantly lower. Multivariate logistic regression identified increasing age (OR 1.04), female gender (OR 2.73), diabetes mellitus (OR 1.89), elevated ALP (OR 1.02), low HDL (OR 1.76), and elevated FBS (OR 1.31) as independent predictors of gallstones in MAFLD. Conclusion In this study, 29.1% of MAFLD patients had GSD. Older age, female gender, diabetes, elevated ALP, low HDL, and high FBS were the factors independently associated with the presence of GSD in MAFLD. Further multi-centered prospective studies incorporating dietary, hormonal, and genetic factors are required for the validation of these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.